Search research articles
Contact Us
Filters
Showing results (161-170 of 176) with videos related to
Page
of 18
Sort By:
Journal of Clinical Medicine
|
May 27, 2023
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement
Maria Concetta Fargnoli, Federico Bardazzi, Luca Bianchi, et al.
Clinical and Experimental Dermatology
|
November 1, 2025
Cumulative clinical benefits of biologic treatments in patients with moderate-to-severe psoriasis: an Italian real-life experience - IL PSO (Italian Landscape Psoriasis)
Diego Orsini, Luca Potestio, Maria Concetta Fargnoli, et al.
Dermatology (Basel, Switzerland)
|
July 14, 2024
Guidelines How to Integrate Surgery and Targeted Therapy with Biologics for the Treatment of Hidradenitis Suppurativa: Delphi Consensus Statements from an Italian Expert Panel
Annamaria Offidani, Angelo Valerio Marzano, Ketty Peris, et al.
The Journal of Dermatological Treatment
|
February 6, 2026
Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER study
Claudio Bonifati, Giuseppe Argenziano, Serena Lembo, et al.
Plos One
|
August 14, 2020
Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis
Emanuele Scala, Matteo Megna, Paolo Amerio, et al.
Dermatology and Therapy
|
January 11, 2021
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations
Paolo Gisondi, Marina Talamonti, Andrea Chiricozzi, et al.
Dermatology and Therapy
|
April 23, 2025
Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis)
Mario Valenti, Luciano Ibba, Sara Di Giulio, et al.
The Journal of Dermatological Treatment
|
May 7, 2024
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis)
Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, et al.
Pharmacological Research
|
April 22, 2026
Comparative risk of serious infections across biological drugs in patients with psoriatic arthritis or psoriasis: a target trial emulation using the Italian VALORE distributed database network
Andrea Spini, Luca L'Abbate, Ylenia Ingrasciotta, et al.
Frontiers in Pharmacology
|
September 4, 2023
Impact of the 2018 revised Pregnancy Prevention Programme by the European Medicines Agency on the use of oral retinoids in females of childbearing age in Denmark, Italy, Netherlands, and Spain: an interrupted time series analysis
Carlos E Durán, Judit Riera-Arnau, Shahab Abtahi, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 176) with videos related to
Sort By:
Page
of 18
Journal of Clinical Medicine
|
May 27, 2023
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement
Maria Concetta Fargnoli, Federico Bardazzi, Luca Bianchi, et al.
Clinical and Experimental Dermatology
|
November 1, 2025
Cumulative clinical benefits of biologic treatments in patients with moderate-to-severe psoriasis: an Italian real-life experience - IL PSO (Italian Landscape Psoriasis)
Diego Orsini, Luca Potestio, Maria Concetta Fargnoli, et al.
Dermatology (Basel, Switzerland)
|
July 14, 2024
Guidelines How to Integrate Surgery and Targeted Therapy with Biologics for the Treatment of Hidradenitis Suppurativa: Delphi Consensus Statements from an Italian Expert Panel
Annamaria Offidani, Angelo Valerio Marzano, Ketty Peris, et al.
The Journal of Dermatological Treatment
|
February 6, 2026
Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER study
Claudio Bonifati, Giuseppe Argenziano, Serena Lembo, et al.
Plos One
|
August 14, 2020
Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis
Emanuele Scala, Matteo Megna, Paolo Amerio, et al.
Dermatology and Therapy
|
January 11, 2021
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations
Paolo Gisondi, Marina Talamonti, Andrea Chiricozzi, et al.
Dermatology and Therapy
|
April 23, 2025
Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis)
Mario Valenti, Luciano Ibba, Sara Di Giulio, et al.
The Journal of Dermatological Treatment
|
May 7, 2024
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis)
Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, et al.
Pharmacological Research
|
April 22, 2026
Comparative risk of serious infections across biological drugs in patients with psoriatic arthritis or psoriasis: a target trial emulation using the Italian VALORE distributed database network
Andrea Spini, Luca L'Abbate, Ylenia Ingrasciotta, et al.
Frontiers in Pharmacology
|
September 4, 2023
Impact of the 2018 revised Pregnancy Prevention Programme by the European Medicines Agency on the use of oral retinoids in females of childbearing age in Denmark, Italy, Netherlands, and Spain: an interrupted time series analysis
Carlos E Durán, Judit Riera-Arnau, Shahab Abtahi, et al.
Page
of 18